Merck’s Keytruda continues to generate billion-dollar sales. The oncology drug reached $4.5 billion of sales in the third quarter, making a cornerstone of Merck’s offerings. Its list price is approximately $175,000 per year.
“Keytruda is close to becoming the highest-selling drug in the world and would be a Fortune 200 company on its own.” Read more here.
(Source: Bob Herman, Axios, 10/29/21)